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ABSTRACT
Alzheimer’s disease, the most common cause of dementia, is characterized by two 
major pathological hallmarks: amyloid plaques and neurofibrillary tangles. Based on 
these two indicators, an amyloid cascade hypothesis was proposed, and accordingly, 
most current therapeutic approaches are now focused on the removal of β-amyloid 
peptides (Aβ from the brain. Additionally, strategies for blocking tau hyperphosphory-
lation and aggregation have been suggested, including the development of drugs that 
can block the formation of tangles. However, there are no true disease-modifying drugs 
in the current market, though many drugs based on theories other than Aβ and tau 
pathology are under development. The purpose of this review was to provide in-
formation on the current development of AD drugs and to discuss the issues related 
to drug development.
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INTRODUCTION
    In  the  last  century,  the  world  transitioned  from  a 
young  to  aging  population  that  increasingly  suffers 
from  major  health  problems  such  as  infectious 
disease  to  chronic  illness.  Especially,  neurodege-
nerative  diseases  are  a  major  concern  in  aged 
countries.  Among  these  diseases,  Alzheimer’s  di-
sease  (AD)  is  the  most  prevalent  with  the  number 
of the patients about 30 million worldwide, and this 
will reach more than 80 million in 2040 (Prince and 
Jackson,  2009).
    AD,  the  most  common  cause  of  dementia,  is  a 
chronic  disorder  characterized  by  a  progressive  de-
cline  in  cognitive  function.  Major  pathological  hall-
marks  include extensive  neuronal loss,  formation  of 
intracellular  neurofibrillary  tangles  (NFT)  and  ex-
tracellular  deposition  of  β-amyloid  peptides  (Aβ). 
Despite  extensive  research,  the  cause  of  sporadic 
AD  (more  than  90%  of  all  AD)  is  still  unknown 
(Brunden  et  al.,  2009;  Bettens  et  al.,  2010).  Ad-
ditionally, there are no true disease-modifying drugs 
in  the  market;  drugs  currently  available  are  ace-
tylcholine  esterase  inhibitors  and  a  N-methyl  D- 
aspartic acid (NMDA) receptor modulator, which are 
for  symptomatic  treatments  only  (Mangialasche  et 
al.,  2010).
    Amyloid  cascade  theory  and  tauopathy  have 
been  proposed  as  the  cause  of  AD  based  on  two 
pathological  hallmarks  (NFT  and  Aβ).  Accordingly, 
drug  development  has  focused  on  the  removal  of Drug  Development  for  Alzheimer’s  Disease:  Recent  Progress 121
Table  1.  AD  Drug  development  to  target  Ab  or  tau
Agent Phase Mechanism  of  action
ACC-001 II Immunotherapy  (active),  Aβ amino-terminal  conjugate
Bapineuzumab  (AAB-001) III Immunotherapy  (passive),  anti-Aβ aminoteminal  MAb*
Solanezumab  (LY2062430) III Immunotherapy  (passive),  anti-Aβ mid-region  MAb
PF-04360365 II Immunotherapy  (passive),  anti-Aβ MAb
Gammagard III Immunotherapy  (passive),  intraveneous  immunoglobulin
Semagasestat  (LY450139)** III γ-secretase  inhibitor
Begacestat  (GSI-953) I γ-secretase  inhibitor
Flurizan  (tarenflurbil)** III γ-secretase  modulator
CTS-21166 II β-secretase  inhibitor
TAK-0707 Preclinical β-secretase  modulator
ELND005  (AZD  103) II Aβ oligomer  formation  breaker
PBT2 II Amyloid  fibril  formation  breaker
PF-04494700  (TTP488) II RAGE  inhibitor
PAZ-417 I PAI-1  inhibitor,  degradation  of  Aβ
Valproic  acid** III GSK  inhibitor
Lithium II GSK  inhibitor
NP-031112  (NP-12) II GSK  inhibitor
Rember  (methylthioninium  chloride) II Preventing  tau  aggregation
Davunetide  (AL-108  and  AL-208) II Preventing  tau  phosphorylation
*MAb:  monoclonal  antibody,  **Clinical  trial  (s)  was  failed.  See t h e  t e x t .
Aβ and NFT from the brain. However, many drugs 
are  currently  under  development  based  on  other 
theories  of  the  etiology  of  AD.  Disease-modifying 
treatments  are  highly  desirable  but  are  thus  far 
unsuccessful.  The  failed  efficacy  of  recent  multi- 
center clinical trials could be due to systematic and 
random  measurement  errors,  as  well  as  improper 
design,  monitoring,  analysis  and  interpretation  (Be-
cker  and  Greig,  2008).  However,  several  of  the 
compounds  currently  being  developed  could  be-
come  drugs  with  additional  technical  innovations 
and  methodological  improvements  for  clinical  trials.
    The purpose of this article was to provide a brief 
overview  on  the  current  development  of  drugs  for 
Alzheimer’s  disease  and  offer  some  prospective 
comments.
DRUG  DEVELOPMENT  TO  TARGET  Aβ 
(TABLE  1)
    The  amyloid  cascade  hypothesis  is  a  compelling 
model  that  the  aberrant  production  of  Aβ 1-42  is 
the  causative  agent  in  the  pathogenesis  of  AD. 
There are many strategic approaches to reduce the 
level  of  toxic  Aβ 1-42  in  the  brain:  (1)  immuno-
therapy, (2) γ-secretase inhibitors, (3) β-secretase 
inhibitors,  (4)  Aβ  oligomerization  inhibitors,  (5) 
inhibitors  that  prevent  transport  of  Aβ from  blood 
to  the  brain,  (6)  degradation  of  Aβ.
Immunotherapy
    Several immunotherapies targeting Aβ have been 
conducted  in  clinical  trials  based  on  previous  data 
on  improved  cognition  in  mouse  models  of  AD 
(Dodart  et  al.,  2002;  Kotilinek  et  al.,  2002;  Lee  et 
al.,  2006).  The  first  generation  vaccine  targeting 
Aβ was AN-1792, but its phase II clinical trial (CT) 
was discontinued due to the development of aseptic 
meningoencephalitis  in  6%  of  patients  (Gilman  et 
al.,  2005).  The  second-generation  vaccine,  ACC- 
001,  was  developed  to  avoid  an  inflammatory 
response  and  currently  undergoing  phase  II  CTs 
(Fagan,  2008a). 
    Passive immunizations have also been attempted. 
Among  them,  bapineuzumab,  a  humanized  mono-
clonal  antibody  targeting  Aβ,  completed  its  phase 
II  trial  in  234  mild  to  moderate  AD  patients. 
Although  it  failed  to  show  a  clear  clinical  benefit,  it 
moved  to  phase  III  CTs  based  on  its  safety  and 
biomarker  data  generated  by  positron  emission 
tomography  (PET)  (Strobel,  2008a).  Recently  its 
highest  dose  (2  mg/kg)  was  abandoned  to  reduce 
the  risk  for  vasogenic  edema  (Strobel,  2009)  but 
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amyloid  load  in  the  brains  (Landhuis,  2010b).  Like 
bapineuzumab, LY2062430 (Solanezumab) and PF- 
04360365  are  monoclonal  antibodies  against  Aβ 
peptide.  The  former  completed  its  phase  I  and  II 
trials  and  is  currently  in  phase  III  (Siemers  et  al., 
2010;  CT  1  and  CT  2  in  ref.),  whereas  the  latter 
completed phase I CTs and is undergoing phase II 
(Landhuis,  2009a;  CT  3  in  ref.).     
    Since  a  mixture  of  intravenous  immunoglobulin 
(IVIg) of human blood contains the antibody against 
Aβ it  could  be  used  to  quench  a  pool  of  Aβ 
(Dodel et al., 2002). In a small trial (24 people) for 
18  months,  IVIg  (Gammagard)  slowed  clinical  de-
cline  and  protected  brains  against  shrinkage.  The 
mechanism  for  protection  against  AD  could  be  due 
to  direct  targeting  of  Aβ by  IVIg  or  an  indirect 
immunomodulatory  effect.  A  larger  (360  AD  pa-
tients)  multi-center  phase  III  trial  is  underway 
(Dodel  et  al.,  2010;  Fagan,  2010e).  There  are 
several  active  (AFFITOPE  AD01  and  AFFITOPE 
AD02,  GSK933776A,  MABT5102A  and  V950)  as 
well  as  passive  (R1450  and  RN  1219)  immuni-
zations  for  Aβ under  development  currently  (Le-
mere  and  Masliah,  2010).
γ-secretase  inhibitors
    Gamma-secretase is the final enzyme involved in 
the  cleavage  of  amyloid  precursor  protein  (APP)  in 
the membrane, and it consists of a complex of four 
different  proteins  (presenilin,  nicastrin,  Aph-1  and 
Pen-2) (Takasugi et al., 2003; Wolfe, 2008). Among 
the  four  proteins  in  the  complex,  presenilin  is  the 
key  enzyme  that  cleaves  APP.  However,  γ-se-
cretase  cleaves  other  proteins  (more  than  50 
protein substrates) in addition to APP, which makes 
finding  an  APP-specific  inhibitor  for  γ-secretase 
very  difficult  (Beel  and  Sanders,  2008).  Further-
more,  presenilin  is  an  unusual  protein  with  more 
than  150  mutations  in  its  gene  that  are  autosomal 
dominant  for  the  early  onset  of  AD  (PS1  mutation 
database  in  ref.).  Many  mutations  discovered  in 
earlier  studies  increase  the  release  of  Aβ 42,  a 
neurotoxic  form  of  Aβ  peptides,  in  the  brain. 
Accordingly,  strategies  for  blocking  its  enzymatic 
activity have been intensely pursued. Regarding γ- 
secretase,  substrate  specificity  is  challenging  be-
cause  it  cleaves  many  substrates  such  as  Notch, 
which  is  an  important  regulator  in  many  physio-
logical  processes  (De  Strooper  et  al.,  1999).
    The  first  in  vivo p r o o f  o f  γ-secretase  as  a  the-
rapeutic  target  of  AD  was  obtained  using  DAPT  in 
a  transgenic  mouse  model,  which  resulted  in  re-
duced  Aβ  in  the  brain  after  oral  administration 
(Dovey  et  al.,  2001;  Lanz  et  al.,  2003).  LY411575 
showed adverse effects on the immune system and 
intestine  in  a  mouse  model,  and  it  was  later  found 
to  have  poor  selectivity  for  APP  over  Notch  (Wong 
et  al.,  2004).  Additionally,  the  side  effects  of 
LY411575  have  prevented  the  viability  of  a  clinical 
trial.  Later,  LY450139  (Semagacestat)  was  deve-
loped  to  avoid  such  adverse  side  effects.  Phase  II 
trials  with  LY450139  was  unusual  to  estimate  the 
clinical endpoint by measuring biomarkers (e. g. the 
plasma  concentration  of  Aβ)  rather  than  measur-
ing  the  cognitive  or  clinical  improvements  (Strobel, 
2007b).  Even  though  LY450139  did  not  have 
excellent  selectivity  for  APP  over  Notch  (E50=1：
2.8),  it  did  move  on  to  phase  III  trials  but  halted 
due  to  the  treatment  group  showing  faster  decline 
in cognition than the placebo group (Strobel, 2007a; 
Martone  et  al.,  2009;  Fagan,  2010d).
    BMS-299897  and  MRK-560  were  developed  for 
improvement of substrate selectivity of γ-secretase, 
and they have been shown to be effective in animal 
models  without  any  sign  of  Notch  inhibition  (Barten 
et al., 2005; Best et al., 2007). However, they were 
not  found  in  the  stage  of  clinical  trials.  GSI-953 
(Begacestat)  also  has  excellent  selectivity  for  APP 
cleavage  over  Notch  (E50=1：16.8)  (Mayer  et  al., 
2008).  Phase  I  CTs  for  GSI-953  have  been  con-
ducted  but  no  data  have  been  disclosed. 
    In addition to classical inhibitor approaches, com-
pounds  that  modulate  the  enzymatic  activity  of  γ- 
secretase  have  been  developed.  Certain  non-ste-
roidal  anti-inflammatory  drugs  (NSAIDs)  have  been 
found  to  reduce  the  amount  of  toxic  Aβ  42 
(McGeer  and  McGeer,  2007).  For  instance,  ta-
renflurbil  (Flurizan),  which  is  the  R-form  of  flur-
biprofen  lacking  COX-inhibitory  activities,  was  the 
first  γ-secretase  modulator  to  be  developed  (Erik-
sen  et  al.,  2003;  Kukar  et  al.,  2007).  Tarenflurbil 
showed promising outcomes in early preclinical and 
clinical  trials.  However,  it  failed  to  show  any  dif-
ference compared to the placebo group in phase III 
CTs  (Green  et  al.,  2009).  This  failure  could  have 
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the  brain,  as  an  earlier  study  (21-day)  did  not 
reduce  Aβ42  in  the  plasma  or  cerebrospinal  fluid 
(CSF)  (Galasko  et  al.,  2007).
    Recent  data  suggest  that  the  mechanism  by 
which  γ-secretase  modulates  NSAIDs  could  be 
based  on  binding  of  the  substrate  (APP  in  this 
case)  rather  than γ-secretase  itself.  Binding of  the 
compounds  to  APP  prevents  dimerization  of  APP 
and shifts the cleavage site such that less toxic Aβ 
fragments  are  produced  (Richter  et  al.,  2010).
    Carriers of mutations in the presenilin gene share 
heterogeneity  among  their  pathological  phenotypes. 
At  the  time  of  its  discovery,  it  was  suggested  that 
the  presenilin  gene  undergoes  gain-of-function  mu-
tations,  but  since  then  more  than  150  mutations 
have  been  identified  (PS1  mutation  database  in 
ref.).  Many  of  the  mutations  were  found  to  be 
reduction-of-function  by  in  vitro  assays  involving 
simpler  organisms  such  as  C.  elegans  (Okochi  et 
al., 2000; Wolfe, 2007). Moreover, conditional knock-
out  of  PS1  in  postnatal  forebrain  leads  to  cognitive 
deficit  in  the  mouse,  suggesting  that  PS1  is  re-
quired  for  normal  neuronal  function  in  the  adults 
(Yu  et  al.,  2001).  This  could  be  a  significant  factor 
in  the  development  of  γ-seretase  inhibitors,  and 
the  cause  of  recent  failures  in  CTs  with  γ-se-
cretase inhibitors could be due to the disturbance of 
normal  presenilin  functions.
BACE  inhibitors 
    Beta-site  amyloid  precursor  protein  cleaving  en-
zyme  (BACE1)  was  cloned  to  measure  the  en-
zymatic  activity  of  β-secretase,  which  is  the  en-
zyme  responsible  for  initiating  Aβ generation  (For 
review,  Cole  and  Vassar,  2008).  Thus,  BACE  is 
one  of  the  best  drug  targets  for  the  therapeutic 
inhibition  of  Aβ production.  Moreover,  it  is  con-
sidered  to  be  a  better  target  than  γ-seretase  for 
disease-modifying  drugs  since  the  knockout  mouse 
of  BACE1  does  not  produce  Aβ and  shows  only 
minor  behavioral  changes  (Cai  et  al.,  2001;  Ro-
berds  et  al.,  2001).  Even  though  the  structure  of 
BACE1  has  been  solved,  the  design  of  potent 
inhibitors  is  still  problematic  since  the  active  site  is 
so large (Hong et al., 2000). CTS-21166 (CoMentis) 
is  the  first  BACE1  inhibitor  tested  in  phase  I  CTs. 
According  to  information  provided  by  the  company, 
CTS-21166  is  safe,  well-tolerated  and  shows  do-
se-related  reduction  in  plasma  Aβ  40  (Strobel, 
2008c). 
    LY2811376,  another  orally  available  and  brain- 
penetrant  inhibitor,  showed  good  tolerance  and 
dose-dependent reduction of plasma Aβ in phase I 
CTs.  However,  its  trials  were  terminated  due  to 
additional  non-clinical  toxicology  data  which  was 
found in the middle of the CTs. Nonetheless, it was 
clearly  demonstrated  that  BACE1  is  a  druggable 
target  (Rogers,  2010).  TAK-0707,  a  promising  non- 
peptidic and lipophilic compound, is non-competitive 
for  substrates  and  results  in  reduction  of  Aβ and 
cognitive  improvement  in  a  mouse  AD  model 
(Fukumoto  et  al.,  2010).  However,  no  CT  on 
TAK-0707 is being currently conducted. Other com-
pounds which are derived from peptidomimetics and 
non-peptides  have  nano-molar  potency  in  in  vitro 
assays.  However,  they  lack  in  vivo  efficacy  data  in 
mouse  models.  (Hills  and  Vacca,  2007)
    Alternatively,  compounds  that  modulate  the  ac-
tivity  of  β-secretase  could  be  candidates  for  AD 
therapeutics.  Posiphen  is  enantiomer  of  phenserine 
and  is  inactive  in  inhibiting  acetylcholine  esterase 
while  phenserine  has  cholinergic  activity  (see  be-
low). Posiphen reduces both Aβ 40 and Aβ 42 in 
mice  and  it  acts  by  reducing  β-secretase  activity 
as  well  as  that  of  APP  transcription  (Lahiri  et  al., 
2007). Recently, recruitment is ongoing for a phase 
I  study  in  subjects  with  amnestic  mild  cognitive 
impairment  (CT  4  in  ref.). 
    The  recent  discovery  that  BACE1-knockout  mice 
produce  excess  sodium  channels  in  their  axons, 
have  increased  neuronal  excitability,  and  are  more 
susceptible  to  seizures  than  normal  mice  sends  a 
caution  to  the  developers  of  BACE1  inhibitors  (Hu 
et  al.,  2010).
Aβ  oligomerization  inhibitors
    Tramiprosate  binds  to  soluble  Aβ and  prevents 
formation of amyloid plaques (Gervais et al., 2001). 
This  drug  was  the  first  to  have  been  developed 
based  on  amyloid  cascade  theory,  reaching  late- 
stage  development.  However,  the  outcome  of  its 
phase III CTs was not conclusive despite promising 
results  in  phase  II  (Wong,  2007).  These  poor  re-
sults  could  have  been  due  to  its  promotion  of  tau 
aggregation  or  unusually  large  placebo  response 
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    Phenserine  was  developed  as  an  inhibitor  of 
acetylcholine  esterase  and  later  demonstrated  cog-
nitive  improvement  in  animal  models.  Use  of 
phenserine  reduced  the  amount  of  APP  by  mo-
dulating APP translation through interaction with the 
5’UTR.  Even  though  moderate  success  was 
attained  in  phase  II,  the  drug  failed  to  show  any 
significant  benefit  over  placebo  in  phase  III  trials 
(Strobel,  2005).  ELND005  (formerly  known  as  AZD 
103)  is  a  scillo-inositol,  one  of  the  8  possible 
stereoisomeric  forms  of  inositol.  It  reduced  the 
accumulation  of  Aβ  oligomers  and  suppressed 
memory  loss  in  transgenic  mice  (Hawkes  et  al., 
2010). Long-term phase II trials using ELND005 did 
not show significant improvements in cognition even 
though  they  showed  the  effects  on  CSF  Aβ 
(Fagan,  2010c).  PBT2,  an  anti-fibrillar  agent,  is  a 
metal-protein-attenuating  compound  that  alters  the 
interaction  between  Aβ and metals.  The  phase IIa 
trial  of  PBT2  showed  the  reduction  of  Aβ 42  in 
CSF without affecting the plasma biomarkers of AD. 
Even  though  no  major  adverse  effects  were  ob-
served,  cognitive  improvement  was  restricted  to  a 
part  of  executive  functions  (Lannfelt  et  al.,  2008).
Inhibitors  of  Aβ  transport:  RAGE  inhibitors
    The receptor for advanced glycation end products 
(RAGE) binds Aβ and transports it from plasma to 
the  brain  via  the  blood-brain  barrier  (Deane  et  al., 
2003).  Thus,  RAGE  has  been  suggested  as  a 
therapeutic target for preventing the accumulation of 
Aβ in  the  brain.  PF-04494700  (formerly  TTP488), 
the  first  RAGE  inhibitor  for  AD,  was  recently 
developed.  Phase  II  CTs  for  evaluation  of  safety 
and  tolerance  have  been  completed.  Currently, 
phase II  for  efficacy is underway  but subjects have 
not  been  recruited  (CT  5  in  ref.).
Degradation  of  Aβ
    Degradation  of  Aβ could  be  the  most  effective 
strategy  for  its  removal  from  the  brain.  There  are 
some  proteases  that  degrade  Aβ,  as  evidenced  in 
vivo  using  knock-out  or  over-expressing  transgenic 
mice.  Such  proteases  are  insulin-degrading  en-
zymes,  including  neprilysin  and  plasmin  activator 
inhibitor-1  (PAI-1)  inhibitor.  The  development  of 
compounds that enhance the degradation of Aβ is 
still  in  the  exploratory  stage.  The  only  compound 
that has reached CTs is PAZ-417, a PAI-1 inhibitor 
(Jacobsen  et  al.,  2008).  Despite  the  possibility  of 
bleeding  by  activation  of  the  plasmin  system,  there 
were  no  severe  side  effects  in  any  animal  model. 
Two  phase  I  trials  have  been  completed  while  a 
third  was  terminated  (CT  6  in  ref.).
DRUG  DEVELOPMENT  FOR  TARGETING 
O F  T A U  P R O T E I N
    Even  if  Aβ is  considered  to  be  the  major  cause 
of  AD  pathology,  tau  could  play  an  important  role 
in  AD  pathogenesis  (Iwatsubo,  2006).  Therefore, 
blocking  tau  could  be  an  effective  therapeutic 
strategy.  Tau  is  a  protein  found  in  the  cytoplasm 
that  binds  to  tubulin  for  the  stabilization  of  mi-
crotubules.  During  AD,  tau  is  hyperphosphorylated, 
resulting in NFTs inside neurons, which are toxic to 
neurons  (Iqbal  et  al.,  1994).  Kinases  that  are 
involved  in  the  hyperphosphorylation  of  tau  are 
considered as drug targets. However, there are not 
many  drug  candidates  compared  to  those  of  Aβ 
pathology.
    A  major  therapeutic  approach  for  tau  pathology 
is  developing  inhibitors  of  kinases  of  tau  hyper-
phosphorylation.  Several  kinases  are  reported  to 
phosphorylate  tau  protein,  including  Glycogen  syn-
thase  kinase  3β  (GSK3β),  cyclin-dependent  ki-
nase 5 (CDK5), extracellular signal-regulated kinase 
(ERK),  P38  and  c-Jun  N-terminal  kinase  (JNK) 
(Iwatsubo,  2006).  Two  well  known  drugs  for  psy-
chiatric  disorders,  valproic  acid  and  lithium,  inhibit 
GSK3  and  reduce  tau  phosphorylation.  Although 
valproic  acid  reached  phase  III  CTs,  it  failed  to 
show  any  improvement  of  neuropsychiatric  symp-
toms in AD patients (Landhuis, 2009a). Lithium also 
failed  to  show  any  change  in  CSF  markers  or 
cognitive  improvement  in  a  small  trial  (Hampel  et 
al.,  2009).
    Among  the  several  GSK3  inhibitors  under  de-
velopment,  NP-031112  (NP-12),  which  is  non-com-
petitive  to  ATP,  reduces  tau  phosphorylation  and 
amyloid  deposits  in  the  brain  of  animal  models 
(Sereno et al., 2009). A phase II trial with this drug 
has  been  completed,  but  the  result  has  not  been 
published.
    Alternatively, there are approaches preventing tau 
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Table  2.  AD  Drug  development  based  on  other  theories
Agent Phase Mechanism  of  action
Dimebon** III Enhancement  of  mitochondria
 f u n c t i o n
Insulin  (intranasal) II Increase  insulin  signal
Gikgo  biloba** III Neuroprotection
Huperzine  A II Neuroprotection  and
  acethylcholine  inhibition
Atorvastatin** III Cholesterol-lowering
NSAID** III Preventing  inflammation
  in  brain
MK-0952 II Phosphodiesterase  4  inhibitor
PF-0447943 I Phosphodiesterase  9A  inhibitor
Vitamin  E* III Anti-oxidation
Omega-3* III Unsaturated  fatty  acid
*The result of CT was inconclusive, **Clinical trial(s) was failed. 
See  the  text.
Methylthioninium chloride (methylene blue, Rember), 
a  widely  used  dye  for  protein  staining,  interferes 
with  tau  aggregation  and  also  enhances  mitochon-
drial  function.  Phase  II  trials  showed  slow  disease 
progression, but efficacy and safety still need to be 
confirmed  in  phase  III  CTs  (Strobel,  2008b). 
    Davunetide  has  been  developed  as  both  an 
intranasally  administered  peptide  of  8  amino  acids 
(AL-108,  NAP)  and  as  an  intravenous  formulation 
(AL-208).  Although  the  neuroprotective  mechanism 
is  not  clear,  AL108  inhibits  tau  hyperphosphory-
lation  and  protects  the  brain  from  Aβ toxicity  in 
animal  models  (Matzuoka  et  al.,  2007).  A  phase  II 
study  on  AL-108  in  patients  with  amnestic  mild 
cognitive  impairment  showed  positive  effects  on 
cognitive  function  (Fagan,  2009a).  However,  the 
study  was  short  (12  weeks)  and  needs  to  be 
confirmed  by  additional  studies.
DRUG  DEVELOPMENT  BASED  ON 
OTHER  THEORIES  (TABLE  2)
    Dimebon,  which  was  developed  as  a  non-se-
lective  antihistamine,  weakly  inhibits  acethylcholine 
esterase  (Bachurin  et  al.,  2001).  It  also  inhibits 
NMDA  receptors  and  voltage-gated  calcium  cha-
nnels,  but  its  neuroprotective  activity  is  mainly 
derived  from  the  enhancement  of  mitochondrial 
function  (Bachurin  et  al.,  2003).  A  phase  II  CT  in 
2007  showed  clear  improvement  for  all  outcome 
measures (Doody et al., 2008). However, the same 
positive  results  were  not  confirmed  in  phase  III 
trials  (Fagan,  2010a).
    Since AD patients show reduced insulin signaling 
in  the  brain  and  diabetes  increases  the  risk  of 
developing dementia, there are many approaches to 
increase insulin in the brain. Recently, a four-month 
phase II study on intranasal administration of insulin 
in  patients  with  MCI  or  early  AD  showed  improved 
cognition  and  daily  function,  with  larger  phase  III 
trials  planned  (Landhuis,  2010a).  Insulin-like  growth 
factor-1  (IGF-1)  is  also  considered  a  treatment  for 
neurodegenerative disorders. However, MK-677 (ibu-
tamoren  mesylate),  a  potent  inducer  of  IGF-1 
secretion,  did  not  benefit  AD  patients  (Sevigny  et 
al.,  2008).  Recent  data  from  IGF-1  receptor  knock- 
out mouse is more confusing: the results suggested 
that  reducing  insulin/IGF-1  signaling  helps  avoid 
dementia  (Fagan,  2009b).  A  clinical  trial  to  assess 
the relationship between the levels of IGF-1 system 
components  and  cognitive  status  in  patients  with 
AD is underway (CT 7). Drugs that modulate insulin 
signaling  have  also  been  developed.  However, 
rosiglitazone  and  pioglitazone,  both  peroxisome 
proliferator-activated receptor-γ (PPARγ) agonists, 
did  not  show  significant  benefits  in  patients  with 
mild  to  moderate  AD  (Strobel,  2006).
    Ginkgo  biloba  is  an  herb  that  is  widely  used  to 
prevent and treat cognitive decline in aging people. 
However,  CTs  conducted  for  six  years  (2002∼
2008)  showed  that  daily  doses  of  standardized 
ginkgo  biloba  leaf  extract  failed  to  delay  the  de-
velopment of AD in 1,545 treated seniors (Dekosky 
et  al.,  2008).  Huperzine  A  is  a  natural  alkaloid 
compound with neuroprotective effects in addition to 
inhibitory  activity  of  acetylcholine  esterase.  Despite 
positive  results  in  phase  II  CTs,  further  trials  are 
not  ongoing  (Wang  et  al.,  2009).
    Elevated levels of cholesterol are associated with 
a  risk  of  AD  (Kivipelto  and  Solomon,  2006),  and 
cholesterol-lowering statins have been suggested to 
reduce  the  risk  of  AD.  A  transgenic  mouse  model 
was  used  to  demonstrate  that  a  high  level  of 
cholesterol  increases  the  production  of  Aβ (Refolo 
et al., 2000). However, clinical studies on treatment 
with  statins  in  patients  with  AD  have  not  produced 
any  beneficial  effects  so  far.  Atorvastatin  failed  to 
show any benefit in phase III trials (Feldman et al., 
2010),  and  trials  with  pitavastatin  or  simvastatin  for 
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(Fagan,  2008b).
    Epidemiological  data  and  a  neuroinflammation 
model  of  AD  suggest  that  NSAID  can  be  effective 
for  the  treatment  and  prevention  of  AD  (Townsend 
and Pratico, 2005; Tuppo and Arias, 2005). To find 
the  relationship  between  NSAIDs  and  AD,  four 
prospective  clinical  studies  were  conducted  and 
they  showed  a  reduced risk  for AD  upon  treatment 
with  NSAIDs.  However,  double  blind  randomized 
CTs with placebo groups failed to show that NSAID 
is  an  effective  treatment  for  prevention  of  AD 
(ADAPT  Research  Group,  2009).  Recent  data  sug-
gest  the  prevention  should  be  done  in  very  early 
stage  of  AD  (Varvel  et  al.,  2009).
    Antagonists  or  agonists  of  many  neurotransmitter 
receptors have been suggested as drug candidates 
for  AD  (Doraiswamy  and  Xiong,  2006),  including 
SB-742457 (serotonergic, 5-HT6 receptor antagonist; 
Maher-Edwards  et  al.,  2010),  PRX-03140  (5-HT4 
agonist,  terminated),  SR57746A  (xaliproden)  and 
Lecozotan  SR  (5-HT1A  receptor  antagonist,  lack  of 
efficacy), SGS-742 (GABAB-receptor antagonist, un-
successful),  AZD3480  (α4β2-selective  neuronal 
nicotinic  receptor  agonist;  Dunbar  et  al.,  2010), 
CX717  (AMPA-type  glutamate  receptor  modulator; 
Hampson  et  al.,  2009)  and  RO5313534  (MEM 
3454, nicotinic α7 receptor agonist; Rezvani et al., 
2009).
    Phosphodiesterase  4  inhibitors  show  neuropro-
tective and neurorengenerative activities in a mouse 
AD  model.  MK-0952  completed  phase  II  trials  in 
patients  with  mild  to  moderate  AD,  but  the  results 
have  not  been  published  and  no  further  clinical 
trials  are  going  (CT  8).  PF-04447943,  which  is  a 
selective phosphodiesterase 9A inhibitor, was tested 
for  its  AD  therapeutic  efficacy.  Phase  I  was  com-
pleted,  and  currently  AD  patients  are  recruiting  for 
phase  II  CTs  (Fagan,  2010b).
    Women  have  higher  risk  than  men  for  AD.  It 
could  be  due  to  changes  in  hormonal  regulation 
after  menopause.  Modulation  of  hormones  has 
been  suggested  as  a  treatment  for  AD  in  women. 
Raloxifene, a selective estrogen receptor modulator, 
was tested for the prevention of cognitive decline in 
postmenopausal  women  with  osteoporosis.  High 
dose  (120  mg/day)  of  raloxifen  reduced  the  risk  of 
mild  cognitive  impairment  (Yaffe  et  al.,  2005; 
Legault  et  al.,  2009).  However,  no  further  deve-
lopment was reported for the drug in the prevention 
of  AD.
    Nerve  growth  factor  (NGF)  supports  survival  and 
fiber  outgrowth  of  basal  forebrain  cholinergic  neu-
rons,  and  data  suggest  NGF  imbalance  activates 
the production of Aβ, leading to neurodegeneration 
in  AD  patients  (Cattaneo  et  al.,  2008).  There  have 
been  many  attempts  to  deliver  NGF  to  basal 
forebrain  cholinergic  neurons.  However,  intracere-
broventricular  infusion  of  NGF  was  interrupted  by 
adverse  effects  (Eriksdotter  Jonhagen  et  al.,  1998). 
Nonetheless,  intracerebral  injection  of  genetically 
modified  cells  producing  NGF  showed  an  overall 
lower  rate  of  cognitive  decline  (Tuszynski  et  al., 
2005).  Encapsulated  biodelivery  of  NGF  cholinergic 
basal  forebrain  neurons  was  also  attempted,  and  it 
increases  expression  of  nicotinic  receptors  and 
cognitive  improvement  (Eriksdotte  et  al.,  2010).
    Neuroreplacement  therapies  for  neurodegenera-
tive  diseases  based  on  stem  cells  have  also  been 
suggested  (Sugaya  and  Merchant,  2008).  Other 
approaches  involving  vitamin  E  or  omega-3  poly-
unsaturated  fatty  acids  have  also  been  attempted 
but  the  results  were  inconclusive  (Freund-Levi  et 
al.,  2006;  Bjelakovic  et  al.,  2007).  Resveratrol,  a 
phenolic  compound  derived  from  grapes  and  red 
wine,  has  neuroprotective  effects  and  has  been 
suggested  for  AD  therapeutics  (Sun  et  al.,  2010).
CONCLUSION
    AD  is  a  complex,  multi-factorial  disorder,  the 
mechanism of which has not been fully understood. 
After  considerable  success  in  the  drug  develop-
ment  of  symptomatic  AD  treatments,  the  clinical 
development of new drugs for treatment of AD has 
resulted  only  in  disappointment.  Considering  recent 
failures  in  clinical  trials,  more  innovative  approa-
ches  are  greatly  needed.  Approaches  based  on  a 
single  target  should  be  revised  because  there  are 
several  levels  of  interactions  (especially  environ-
ment)  in  AD  pathogenesis.  Therefore,  mutli-target 
therapies should be considered more seriously, with 
mitochondrial  protection  and  multi-target  directed 
ligands  serving  as  recent  examples.
    Most  of  the  positive  results  in  AD  animal  models 
have  not  been  recapitulated  in  clinical  trials,  which 
implies  that  the  current  animal  models  for  AD  drug Drug  Development  for  Alzheimer’s  Disease:  Recent  Progress 127
development  should  be  reconsidered.  Especially, 
rodent models might have a more powerful ability to 
recover brain cells compared to that of human brain 
(Harrison  et  al.,  2010).
    Many studies suggest that certain lifestyle factors 
could  modify  the  risk  of  developing  AD.  Among 
them, physical exercise may be an effective way to 
reduce  the  risk  of  AD.  It  has  been  demonstrated 
that  physical  exercise  increases  the  many  factors 
involved  in  neurogenesis  (e.g.  BDNF,  TrkB,  CREB, 
IGF-1),  contribute  to  Aβ clearance,  and  improve 
cognition  in  animals  (Vaynman  et  al.,  2003;  Plou-
ghman  et  al.,  2007).
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